Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
about
The potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experienceEstimating the population-level impact of vaccines using synthetic controls.Bronchiectasis in Children: Current Concepts in Immunology and MicrobiologyHaemophilus influenzae type b as an important cause of culture-positive acute otitis media in young children in Thailand: a tympanocentesis-based, multi-center, cross-sectional study.Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trialA reflection on invasive pneumococcal disease and pneumococcal conjugate vaccination coverage in children in Southern Europe (2009-2016)A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and MaCost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese ChildrenImpact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children--a population-based study.Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia.Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the PhilippinesComment on: "Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children".Reply to Farkouh RA et al. Comment on "Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus Influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children"Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine.Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.Vaccination Programs for Endemic Infections: Modelling Real versus Apparent Impacts of Vaccine and Infection Characteristics.Healthcare-seeking behaviour of primary caregivers for acute otitis media in children aged 6 months to <30 months in Panama: results of a cross-sectional surveyImpact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study.Haemophilus haemolyticus Interaction with Host Cells Is Different to Nontypeable Haemophilus influenzae and Prevents NTHi Association with Epithelial CellsAetiology of childhood pneumonia in a well vaccinated South African birth cohort: a nested case-control study of the Drakenstein Child Health Study.Issues in pediatric vaccine-preventable diseases in low- to middle-income countriesReactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2-4 years: A phase II randomized study.Response to Wu et al. - Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong.Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland.Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status.Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.Etiology of Acute Otitis Media in Children Less Than 5 Years of Age: A Pooled Analysis of 10 Similarly Designed Observational Studies.Etiology of acute otitis media and serotype distribution of Streptococcus pneumoniae and Haemophilus influenzae in Chilean children <5 years of age.Antibody persistence and immunologic memory in children vaccinated with 4 doses of pneumococcal conjugate vaccines: Results from 2 long-term follow-up studies.Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vac10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children.Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough.Glycoconjugate vaccines: an update.Further available immunization option to prevent pneumococcal disease.Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in MalaysiaRecurrent Acute Otitis Media: What Are the Options for Treatment and Prevention?Nontypeable Haemophilus influenzae and chronic obstructive pulmonary disease: a review for clinicians.Overall effectiveness of pneumococcal conjugate vaccines: an economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.Recent Developments in Pediatric Community-Acquired Pneumonia.
P2860
Q28088507-0ADBDFF7-5F25-47BB-A8CC-90FE78E883A4Q30398164-99EC7385-DB3C-4101-8A60-281EAB76B6A6Q33734772-AC33BBF7-6C39-4943-964C-18A27F86FEC5Q33823089-9850F180-55DB-4E03-908F-B443BE8AA31CQ33848675-62E1947A-B2B2-427C-8AB9-77197AAACBFAQ33848708-CE1F7721-08C8-42DD-A62E-A27BA7E139C5Q34867264-AA40809C-F810-429E-ACD9-1DD90221A00CQ35186834-306D0CE0-FDAC-445B-B3B1-68922862672DQ35189319-8671EAEC-AA84-4B6F-A038-6E31E180FE30Q35425552-C5AECC13-130C-4CC4-A703-088E2185F452Q35679740-470D6CB0-738A-47BF-8718-21738BB3C968Q35752767-664E478E-F380-44CF-A4B0-019420F53C03Q35752770-9210968D-44E4-4DEA-83AE-5AD7A7D36374Q35813537-B4E9C47A-2060-4FDE-A91F-A63B791B08AFQ35887689-E91B6473-EFC5-4832-90C1-0EB3948D9116Q36180041-DF044AC1-9354-4F31-99F8-D552F3B38ABDQ36241107-7E257D9A-520B-41D1-9D96-31C557BE0B69Q36294037-359976CE-A33A-4B15-9BD2-AF95A0E74B23Q36881633-7E6A3613-99C6-46EF-A06B-95DCA2CB91FEQ37184742-60639FF6-0925-4B75-819D-69B05E623F6EQ37264972-2B8E4EF7-5473-4E41-B37E-5EA14BE1246AQ37309298-71BFDE5E-B158-4312-BFAB-F263F7B4C414Q37375921-C73515C4-7A68-4679-BB3E-7EE557571843Q37445704-6F4974CF-D357-448A-BEC2-28894E4972F1Q37516888-29FBADBD-F7CC-4648-A65D-8F71B8DD4BB2Q37606399-DE8E3CFC-9C60-4281-BFB1-FDFDF39F61DDQ37631215-508E90F7-9042-4FCC-B883-F49A8574D262Q37645986-8AA58E49-B042-4C56-B215-832655424EF6Q37646595-8A31A0C4-8C3B-48D5-994C-1EEAB9CA58BAQ37713768-0F9FF1ED-C29F-4371-969A-63E0EB8266BFQ37713787-50341F95-DC6D-4C56-AB61-B3013FAC2C33Q38246355-375E8649-3BFF-4E9C-8E0F-E9966DF5CC70Q38255287-21A824DC-C635-419F-A8E4-DCF89C34CF37Q38286346-A7450A9E-C064-4DCC-95EB-0577CCE36C08Q38417942-4FC1FA3A-596E-479D-B693-E6F40055E474Q38602904-FC97614E-A001-4138-96CF-7505D3684AACQ38670907-667850A5-42B6-4A85-B1B1-409B1EE8184FQ38679715-7C29065A-D6F3-43C4-99E1-38762FE9144DQ38682554-CDC8DB1A-997F-452E-96E3-A71E955AA654Q38767450-6DB9323D-CB38-4F48-B8F5-CF0FBAD02CA9
P2860
Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy of pneumococcal nonty ...... d randomized controlled trial.
@ast
Efficacy of pneumococcal nonty ...... d randomized controlled trial.
@en
type
label
Efficacy of pneumococcal nonty ...... d randomized controlled trial.
@ast
Efficacy of pneumococcal nonty ...... d randomized controlled trial.
@en
prefLabel
Efficacy of pneumococcal nonty ...... d randomized controlled trial.
@ast
Efficacy of pneumococcal nonty ...... d randomized controlled trial.
@en
P2093
P2860
P1433
P1476
Efficacy of pneumococcal nonty ...... d randomized controlled trial.
@en
P2093
Adriana Pósleman
Alejandro Lepetic
Alexandra Sierra
Ana Ceballos
Ana Leandro
Andrea Falaschi
Arlene Calvo
COMPAS Group
Carlos Carabajal
Carlos Cortes-Barbosa
P2860
P304
P356
10.1371/JOURNAL.PMED.1001657
P407
P577
2014-06-03T00:00:00Z